7bq1 Citations

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates.

Abstract

Most triacylglycerol-lowering fibrates have been developed in the 1960s-1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPARα), was identified. Twenty-one ligand-bound PPARα structures have been deposited in the Protein Data Bank since 2001; however, binding modes of fibrates and physiological ligands remain unknown. Here we show thirty-four X-ray crystallographic structures of the PPARα ligand-binding domain, which are composed of a "Center" and four "Arm" regions, in complexes with five endogenous fatty acids, six fibrates in clinical use, and six synthetic PPARα agonists. High-resolution structural analyses, in combination with coactivator recruitment and thermostability assays, demonstrate that stearic and palmitic acids are presumably physiological ligands; coordination to Arm III is important for high PPARα potency/selectivity of pemafibrate and GW7647; and agonistic activities of four fibrates are enhanced by the partial agonist GW9662. These results renew our understanding of PPARα ligand recognition and contribute to the molecular design of next-generation PPAR-targeted drugs.

Articles - 7bq1 mentioned but not cited (2)

  1. PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates. Kamata S, Oyama T, Saito K, Honda A, Yamamoto Y, Suda K, Ishikawa R, Itoh T, Watanabe Y, Shibata T, Uchida K, Suematsu M, Ishii I. iScience 23 101727 (2020)
  2. Preparation of co-crystals of human PPARα-LBD and ligand for high-resolution X-ray crystallography. Kamata S, Oyama T, Ishii I. STAR Protoc 2 100364 (2021)


Reviews citing this publication (5)

  1. Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα. Tahri-Joutey M, Andreoletti P, Surapureddi S, Nasser B, Cherkaoui-Malki M, Latruffe N. Int J Mol Sci 22 8969 (2021)
  2. The Role of PPAR Alpha in the Modulation of Innate Immunity. Grabacka M, Pierzchalska M, Płonka PM, Pierzchalski P. Int J Mol Sci 22 10545 (2021)
  3. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Kamata S, Honda A, Ishii I. Biomolecules 13 1264 (2023)
  4. Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases. Kim IS, Silwal P, Jo EK. Cells 12 650 (2023)
  5. Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs). D'Aniello E, Amodeo P, Vitale RM. Mar Drugs 21 89 (2023)

Articles citing this publication (16)